Core Viewpoint - Inventiva, a clinical-stage biopharmaceutical company, is set to present its 2024 full-year financial results on March 27, 2025, highlighting its focus on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other unmet medical needs [1][2]. Company Overview - Inventiva specializes in oral small molecule therapies aimed at treating MASH and other diseases with significant unmet medical needs [4]. - The company is currently conducting the NATiV3 pivotal Phase 3 clinical trial for lanifibranor, a novel pan-PPAR agonist targeting adult patients with MASH [4]. - Inventiva has a scientific team of approximately 90 experts in various fields, including biology, medicinal chemistry, and clinical development [5]. - The company possesses a library of around 240,000 pharmacologically relevant molecules, with about 60% being proprietary [5]. - Inventiva is publicly listed on Euronext Paris and NASDAQ under the ticker IVA [6].
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results